文献速递白血病淋巴瘤浆细胞疾病

CD38作为嵌合抗原受体T细胞的泛血液肿瘤靶点

CD38 as a pan-hematologic target for chimeric antigen receptor T cells.
PubMed 文献 · Blood Adv · 2023-01-01

本文开发了靶向人CD38的嵌合抗原受体T细胞(CART-38),用于治疗多发性骨髓瘤、T细胞急性淋巴细胞白血病和急性髓系白血病三种血液恶性肿瘤。在异种移植小鼠模型中,CART-38可介导对上述肿瘤细胞系及原代样本的排斥并延长生存;但在正常人造血异种移植模型中,CART-38导致造血祖细胞的预期减少,提示临床转化时需谨慎监测该潜在毒性。

要点

  • CART-38在体外和异种移植小鼠中对多发性骨髓瘤、T-ALL和AML均有抗肿瘤活性。
  • 活化T细胞上的CD38表达不影响CART-38的扩增或体外功能。
  • 正常人造血异种移植模型中CART-38导致造血祖细胞预期减少,临床转化需谨慎监测。

核心结论

  • CART-38可作为一种统一方法治疗多发性骨髓瘤、T细胞急性淋巴细胞白血病和急性髓系白血病三种CD38表达的血液恶性肿瘤。

研究设计与样本

  • 本研究为临床前研究,开发了靶向人CD38的嵌合抗原受体T细胞(CART-38),并在体外及异种移植小鼠模型中评估其对AML、T-ALL和MM细胞系及原代样本的作用。

主要发现

  • 活化T细胞上的CD38表达未损害CART-38细胞的扩增或体外功能。
  • 在异种移植小鼠中,CART-38介导了对AML、T-ALL和MM细胞系及原代样本的排斥并延长生存。
  • 在正常人造血异种移植模型中,CART-38导致造血祖细胞的预期减少。

临床怎么用

  • 原文结论未据此给出临床推荐;作者指出将这一新免疫疗法转化至临床时,需谨慎并仔细监测造血祖细胞减少这一潜在毒性。

局限性

  • 在正常人造血异种移植模型中CART-38导致造血祖细胞的预期减少,作者指出转化至临床时需谨慎并仔细监测这一潜在毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells engineered to express CARs for a specific cell-surface antigen. CD38 is a validated tumor antigen in multiple myeloma (MM) and T-cell acute lymphoblastic leukemia (T-ALL) and is also overexpressed in acute myeloid leukemia (AML). Here, we developed human CD38-redirected T cells (CART-38) as a unified approach to treat 3 different hematologic malignancies that occur across the pediatric-to-adult age spectrum. Importantly, CD38 expression on activated T cells did not impair CART-38 cells expansion or in vitro function. In xenografted mice, CART-38 mediated the rejection of AML, T-ALL, and MM cell lines and primary samples and prolonged survival. In a xenograft model of normal human hematopoiesis, CART-38 resulted in the expected reduction of hematopoietic progenitors, which warrants caution and careful monitoring of this potential toxicity when translating this new immunotherapy into the clinic. Deploying CART-38 against multiple CD38-expressing malignancies is significant because it expands the potential for this novel therapy to affect diverse patient populations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023. PMID: 37171449. doi:10.1182/bloodadvances.2022007059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。